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Abstract 
ABSTRACT 
Review on inv(11)(p15q23) NUP98/KMT2A with 
data on clinics and on the genes involved. 
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Identity 
Note 
inv(11)(p15q23) is an heterogeneous disease, since a 
NUP98/KMT2A hybrid gene and fusion protein was 
detected in only 2 cases (Kaltenbach et al., 2010), 
whereas there was no evidence of involvement of 
KMT2A (MLL) in 2 other cases (Harrison et al., 
1998). We herein review 21 cases of 
inv(11)(p15q23), most of them were not studied at 
the gene level. Was excluded in this review a case of 
precursor B-ALL where the inv(11)(p15q23) had 
instead a hidden MLL/ENL hybrid gene (Meyer-
Monard et al., 2006). inv(11)(p15q23) has also been 
found in a case of breast adenocarcinoma, an 
adenocarcinoma of the ovary, a case of myxoid 
chondrosarcoma and a mesenchymal tumor, NOS of 
the corpus uteri, and are not herein reviewed 
(Mitelman database). 
Clinics and pathology 
Disease 
inv(11)(p15q23) has been found in myelodysplasia, 
acute myeloid leukemia, treatment related leukemia, 
acute lymphocytic leukemia, hairy cell leukemia, 
multiple myeloma, peripheral T-cell lymphoma. 
Phenotype/cell stem origin 
There were 4 cases of myelodysplasia: a chronic 
myelomonocytic leukemia (CMMoL), a refractory 
anemia with excess blasts in transformation 
(RAEBt), and 2 myelodysplastic syndromes (MDS) 
not otherwise specified (NOS). (Bielorai et al., 2003; 
Harrison et al. et al., 1998; Inaba et al., 1988; Nebral 
et al., 2005). 
There were 9 cases of acute myeloid leukemia: 2 
cases of acute myeloblastic leukemia without 
maturation (FAB type M1), 3 cases of acute 
myeloblastic leukemia with maturation (FAB type 
M2), 1 case of acute promyelocytic leukaemia 
(AML- M3), 2 cases of acute myelomonocytic 
leukemia AML- M4), and 1 case of acute myeloid 
leukemia, NOS (Casas et al., 2003; Harrison et al., 
1998; Kaltenbach et al., 2010; Larramendy et al., 
2002; Nebral et al., 2005; Odero et al., 2001; Xu et 
al., 2001; Yan et al., 2001). 
There were 4 cases of treatment related myeloid 
malignancy: 1 RAEBt after Hodgkin disease and a 
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therapy-related RAEBt evolving toward AML-M5, 
and two FAB type M4 AML, one of which occurred 
after treatment of ALL. (Harrison et al., 1998; 
Nichols et al., 2002; Pui et al., 1989; Secker-Walker 
et al., 1998).  
 
There was a case of childhood ALL (Heerema et al., 
1992), a hairy cell leukemia (Haglund et al., 1994), 
a multiple myeloma (Sawyer et al., 2014), and a 
peripheral T-cell lymphoma (Lepretre et al., 2000).  
 
The only 2 cases where NUP98/KMT2A fusion was 
ascertained were cases of M1 and M2 AMLs in a 
male patient aged 79 years and a female patient aged 
30 years. Both patients died of disease. The 
inv(11)(p15q23) was the sole chromosome 
abnormality (Kaltenbach et al., 2010). 
Epidemiology 
Myeloid malignancy cases were 8 male and 9 female 
patients, median age was 40-44 years, range 2-79 
years, with 5 children cases. Lymphoid malignancy 
cases sex ratio and ages were: 1M/3F, 17 yrs, 40 yrs, 
53 yrs. 
Prognosis 
Data on survival is too scarce. 
Cytogenetics 
Cytogenetics morphological 
In myeloid cases, the inv(11)(p15q23) was the sole 
anomaly, at least within a subclone, in thirteen cases, 
and was accompanied with +8 in two , -7/del(7q) in 
two, -5 in one, a complex karyotype in one case and 
with a t(15;17) in the M3-AML case.  
In lymphoid malignancy cases, the inv(11) was 
accompanied with del(6q) in two cases, and part of a 
complex karyotype in 2. 
Genes involved and 
proteins 
As said above, there was no evidence of involvement 
of KMT2A (MLL) in 2 cases (Harrison et al., 1998), 
whereas there was an in-frame fusion transcript 
between NUP98 and KMT2A in 2 patients 
(Kaltenbach et al., 2010).  
An hemizygous deletion of DDX10 and ATM was 
detected in one case (Nebral et al., 2005) 
NUP98 (nucleoporin 98 kDa) 
Location 
11p15.4 
Note 
Data from Mohamed, 2016 follows: 
DNA/RNA 
NUP98 is one of several genes located in the 
imprinted gene domain of chromosome 11p15.  
Combined haploinsufficiency of NUP98 and RAE1 
has been shown to result in premature separation of 
sister chromatids, leading to severe aneuploidy. 
NUP98 plays roles in gene expression, mitotic 
spindle formation, and cell cycle progression.  
 
NUP98 gene is fused to a large number of "partner 
genes" caused primarily by balanced translocations 
and inversions which are associated with a wide 
variety of hematological malignancies including 
AML and MDS (de novo and therapy related), CML-
blast crisis, and pre T- ALL. To date, no NUP98 
fusion gene has been described in B-cell 
malignancies. At least 30 different partner genes are 
reported to fuse with NUP98; 50% of which are 
homeobox genes. Approximately 10% of patients 
with NUP98 fusions have T-ALL; most commonly, 
these malignancies are associated with NUP98-
RAP1GDS1 gene fusions.  This suggests that 
different partner genes are associated with different 
leukemia, although such associations are rarely 
exclusive. Although NUP98 breakpoints in these 
translocations are variable located between introns 9 
to 14, a chimeric transcript consisting of the 5' 
portion of NUP98 fused in-frame to the 3' portion of 
the partner genes is generated in all. 
Protein 
NUP98 gene encodes two alternatively spliced 
mRNA variants: NUP98 and NUP98-NUP96 that 
are cleaved to produce two distinct nucleoporins, 
NUP98 and NUP96. The NUP98 is a 98 kDa protein 
component of the nuclear pore complex (NPC) 
family which is involved in the trafficking of RNA 
and protein between the nucleus and cytoplasm. The 
NUP98 protein contains two partially characterized 
functional domains: a GLFG repeat region, which 
serves as a nuclear transport receptor docking 
surface, and a GLEBS domain, which mediates the 
interaction with the RAE1 mRNA nuclear export 
factor. Both domains are located within the N-
terminal portion of NUP98.  The chimeric NUP98 
protein that results from translocations always 
retains the intact N-terminal GLFG repeats of 
NUP98 and the C-terminal domain of the partner 
protein. NUP96 is a scaffold component of the NPC 
(Mohamed, 2016). 
KMT2A (myeloid/lymphoid or mixed 
lineage leukemia) 
Location 
11q23.3 
DNA/RNA 
37 exons, spanning about 120 kb; 13-15 mRNA 
Protein 
3969 amino acids, 431 kDa; Transcriptional 
regulatory factor. MLL is known to be associated 
with more than 30 proteins, including the core 
components of the SWI/SNF chromatin remodeling 
complex and the transcription complex TFIID. MLL 
binds promotors of HOX genes through acetylation 
and methylation of histones. MLL is a major 
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regulator of hematopoesis and embryonic 
development, through regulation of HOX genes 
expression regulation (HOXA9 in particular). 
Result of the chromosomal 
anomaly 
Hybrid gene 
in-frame fusion transcript between exon 13 of 
NUP98 and exon 2 of KMT2A (Kaltenbach et al., 
2010). 
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